First Command Bank’s MiNK Therapeutics INKT Stock Holding History

First Command Bank’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.17K	Buy	+103	New	+$2.06K	﹤0.01%	389

Other funds holding INKT

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Command Bank's INKT Position: Q2 2023 in Review

First Command Bank opened a new position in MiNK Therapeutics (INKT) in Q2 2023: 103 shares worth $2.17K. The stake represents ﹤0.01% of the portfolio and ranks #389 among its holdings.

42 funds tracked by Wall St. Rank hold INKT as of Q2 2023.

First Command Bank held 103 shares of MiNK Therapeutics worth $2.17K as of Q2 2023.
MiNK Therapeutics was a new First Command Bank position in Q2 2023.
MiNK Therapeutics made up ﹤0.01% of First Command Bank's portfolio in Q2 2023, its #389 holding.
42 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2023.

Based on First Command Bank's 13F filing for Q2 2023, filed 21 Jul 2023.